Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature Medicine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm.2054PMID 19898489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stable knockdown of microRNA in vivo by lentiviral vectors

  2009cited by this paper
• Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

  2008cited by this paper
• Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays

  2008cited by this paper
• Myelodysplastic syndromes.

  2008cited by this paper
• MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

  2008cited by this paper
• MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

  2008cited by this paper
• High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival.

  2008cited by this paper
• Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells

  2008cited by this paper
• MicroRNA expression profiles of human leukemias

  2008cited by this paper
• TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice

  2008cited by this paper
• Distinct microRNA expression profiles in acute myeloid leukemia with common translocations

  2008cited by this paper
• Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.

  2008cited by this paper
• MicroRNA expression in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Myelodysplastic syndromes: the complexity of stem-cell diseases

  2007cited by this paper
• Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88

  2007cited by this paper
• Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

  2007cited by this paper
• The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.

  2007cited by this paper
• Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes

  2007cited by this paper
• MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

  2007cited by this paper
• Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

  2006cited by this paper
• Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies

  2006cited by this paper
• Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment.

  2006cited by this paper
• Site-specific Lys-63-linked Tumor Necrosis Factor Receptor-associated Factor 6 Auto-ubiquitination Is a Critical Determinant of IκB Kinase Activation*

  2006cited by this paper
• NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses

  2006cited by this paper
• Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis

  2006cited by this paper
• Activation of Vascular Endothelial Growth Factor Receptor-2 in Bone Marrow Leads to Accumulation of Myeloid Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor1

  2005cited by this paper
• Analysis of myelodysplastic syndromes with complex karyotypes by high‐resolution comparative genomic hybridization and subtelomeric CGH array

  2005cited by this paper
• Interleukin-6: from basic science to medicine--40 years in immunology.

  2005cited by this paper
• Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome.

  2004cited by this paper
• Intensified Cloning Efforts Have Revealed Numer

  2004cited by this paper
• Mal Interacts with Tumor Necrosis Factor Receptor-associated Factor (TRAF)-6 to mediate NF-κB Activation by Toll-like Receptor (TLR)-2 and TLR4*

  2004cited by this paper
• Simultaneous Demonstration of Clonal Chromosome Abnormalities and Apoptosis in Individual Marrow Cells in Myelodysplastic Syndrome

  2004cited by this paper
• Prediction of mammalian microRNA targets.

  2003cited by this paper
• Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34

  2002cited by this paper
• Circulating Levels of Thrombopoietic and Inflammatory Cytokines in Patients with Acute Myeloblastic Leukemia and Myelodysplastic Syndrome

  2002cited by this paper
• HOXB4-induced expansion of adult hematopoietic stem cells ex vivo.

  2002cited by this paper
• Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

  2002cited by this paper
• TAK1 is a ubiquitin-dependent kinase of MKK and IKK

  2001cited by this paper
• HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation.

  2001cited by this paper
• Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.

  2001cited by this paper
• Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.

  2000cited by this paper
• Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes.

  1999cited by this paper
• Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

  1999cited by this paper
• Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells

  1997cited by this paper
• Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus

  1992cited by this paper
• Measurement of serum cytokine levels in patients with myelodysplastic syndromes.

  1992cited by this paper
• Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.

  1992cited by this paper
• Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

  1990cited by this paper

• Hema-CRISPR: A clone-based protocol for effective genetic editing of hematopoietic stem cells.

  2026cites this paper
• Biomarkers of Common Molecular Dysregulation in Tumor Tissue and Peritumor Mucosa in Head and Neck SCC: Insights into Field Cancerization

  2026cites this paper
• Role of Non-Coding RNAs in Acute Myeloid Leukemia

  2025cites this paper
• Unlocking the Potential of miRNAs in Sepsis Diagnosis and Prognosis: From Pathophysiology to Precision Medicine

  2025cites this paper
• IRAK signaling in cancers: mechanisms, targeting, and clinical implications

  2025cites this paper
• Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

  2025cites this paper
• Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance

  2025cites this paper
• Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1

  2025cites this paper
• A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discovery.

  2025cites this paper
• SRSF2-mutated MDS: bortezomib STAT?

  2025cites this paper
• The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation

  2025cites this paper
• Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

  2025cites this paper
• Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region

  2025cites this paper
• Dual role of mir-146a in non-small cell lung cancer progression: Molecular mechanisms and clinical potential.

  2025cites this paper
• Advances and challenges in the treatment of myelodysplastic syndromes

  2025cites this paper
• Inflammatory signaling in the pathogenesis of acute myeloid leukemia

  2025cites this paper
• Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions

  2025cites this paper
• Standardizing Immunophenotyping Research Tools to Improve MDS and the Immune System

  2024cites this paper
• Immune‐dysregulation harnessing in myeloid neoplasms

  2024cites this paper
• Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

  2024cites this paper
• Inflamma-miRs Profile in Myelodysplastic Syndrome Patients

  2024cites this paper
• Loss of FBXO11 function establishes a stem cell program in acute myeloid leukemia through dysregulation of mitochondrial LONP1

  2024cites this paper
• A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

  2024cites this paper
• Pathogenesis and inflammaging in myelodysplastic syndromes

  2024cites this paper
• Genome sequencing in the management of myelodysplastic syndromes and related disorders

  2024cites this paper
• K33 only mutant ubiquitin augments bone marrow‐derived dendritic cell‐mediated CTL priming via PI3K‐Akt pathway

  2024cites this paper
• Bone marrow inflammation in haematological malignancies

  2024cites this paper
• STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response

  2024cites this paper
• Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression

  2024cites this paper
• MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response

  2024cites this paper
• Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.

  2024cites this paper
• Lacticaseibacillusparacasei BNCC345679 revolutionizes DSS-induced colitis and modulates gut microbiota

  2024cites this paper
• Epigenetic regulation of megakaryopoiesis and platelet formation

  2024cites this paper
• Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML

  2024cites this paper
• miR-145 and incident thromboembolism.

  2024cites this paper
• Cellular and immunotherapies for myelodysplastic syndromes.

  2024cites this paper
• Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer

  2024cites this paper
• Insight into microRNAs’ involvement in hematopoiesis: current standing point of findings

  2023cites this paper
• The value of serum IL-4 to predict the survival of MDS patients

  2023cites this paper
• The Role of Non-Coding RNAs in Myelodysplastic Neoplasms

  2023cites this paper
• [Pathophysiology of myelodysplastic syndromes].

  2023cites this paper
• In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms.

  2023cites this paper
• Ribosome biogenesis in disease: new players and therapeutic targets

  2023cites this paper
• Protocol for performing consecutive bone marrow transplants in mice to study the role of marrow niche in supporting hematopoiesis

  2023cites this paper
• Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies

  2023cites this paper
• Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement.

  2023cites this paper
• Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia.

  2023cites this paper
• Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).

  2023cites this paper
• Single cell profiling of del(5q) MDS unveils its transcriptional landscape and the impact of lenalidomide

  2023cites this paper
• ABIN1 (Q478) is Required to Prevent Hematopoietic Deficiencies through Regulating Type I IFNs Expression

  2023cites this paper
• Exploring the impact of miR-128 in inflammatory diseases: A comprehensive study on autoimmune diseases.

  2023cites this paper
• Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation

  2023cites this paper
• Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review

  2023influential citation
• Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia

  2023cites this paper
• New Insights into the Nature of the 5q- Deletion Syndrome Based on Quantitative Measurement of BAALC- Expressing Stem Cell Burdens

  2023cites this paper
• Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes

  2023cites this paper
• Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment

  2023cites this paper
• STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity

  2023cites this paper
• IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

  2023cites this paper
• PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

  2023cites this paper
• The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies

  2023cites this paper
• Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs

  2023cites this paper
• Control of focal adhesion kinase activation by RUNX1-regulated miRNAs in high-risk AML

  2023influential citation
• Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment

  2022cites this paper
• Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes

  2022cites this paper
• A low carbohydrate diet high in fish oil and soy protein delays inflammation, hematopoietic stem cell depletion, and mortality in miR-146a knock-out mice

  2022influential citation
• Clonal hematopoiesis and bone marrow inflammation.

  2022cites this paper
• Different modalities of host cell death and their impact on Mycobacterium tuberculosis infection.

  2022cites this paper
• Role of microRNA in Endocrine Disruptor-Induced Immunomodulation of Metabolic Health

  2022cites this paper
• TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.

  2022cites this paper
• Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS

  2022cites this paper
• EVALUATION OF MIR-145 AND MIR-146A AS POTENTIAL BIOMARKERS FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

  2022cites this paper
• Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

  2022cites this paper
• MicroRNAs as Regulators of Cancer Cell Energy Metabolism

  2022cites this paper
• Autophagy-related Proteins in Genome Stability: Autophagy-Dependent and Independent Actions

  2022cites this paper
• Progressive Host-Directed Strategies to Potentiate BCG Vaccination Against Tuberculosis

  2022cites this paper
• Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia

  2022cites this paper
• Targeting cereblon in hematologic malignancies.

  2022cites this paper
• Upregulation of microRNA‐597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition

  2022cites this paper
• Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia

  2022cites this paper
• Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia

  2022cites this paper
• Chronic inflammation suppresses del(5q)-like MDS HSCs via p53

  2022cites this paper
• A single allele of the hsa-miR-302/367 cluster maintains human pluripotent stem cells

  2022cites this paper
• Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review

  2022cites this paper
• The Coming of Age of Preclinical Models of MDS

  2022cites this paper
• Inflammation and myeloid malignancy: Quenching the flame.

  2022cites this paper
• Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

  2022cites this paper
• Myelodysplastic Syndrome: Diagnosis and Screening

  2022cites this paper
• TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice

  2022cites this paper
• Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

  2022influential citation
• Pathogenic Mechanisms in Acute Myeloid Leukemia

  2022cites this paper
• Human rDNA and Cancer

  2021cites this paper
• MiR-145-5p Inhibits the Invasion of Prostate Cancer and Induces Apoptosis by Inhibiting WIP1

  2021cites this paper
• Differentiation therapy for myeloid malignancies: beyond cytotoxicity

  2021cites this paper
• Roles of ribosomal proteins in hematologic disorders and cancers: a review

  2021cites this paper
• IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies

  2021cites this paper
• Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia

  2021cites this paper
• Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

  2021cites this paper
• Therapeutic targeting of the inflammasome in myeloid malignancies

  2021cites this paper
• Inflammation in Myeloid Malignancies: From Bench to Bedside.

  2021cites this paper